Top 10 Companies in the (2S)-1-(Chloroacetyl)-2-pyrrolidinecarbonitrile (CAS No. 207557-35-5) Market (2026): Market Leaders Powering Global Pharmaceutical Intermediate Supply

MARKET INSIGHTS

Global (2S)-1-(Chloroacetyl)-2-pyrrolidinecarbonitrile (CAS No. 207557-35-5) market size was valued at USD 28.4 million in 2025. The market is projected to grow from USD 30.1 million in 2026 to USD 52.6 million by 2034, exhibiting a CAGR of 6.4% during the forecast period.

(2S)-1-(Chloroacetyl)-2-pyrrolidinecarbonitrile is a chiral pharmaceutical intermediate bearing a chloroacetyl group attached to a pyrrolidine ring with a nitrile functionality at the 2-position in the (S)-configuration. This compound serves as a key building block in the synthesis of dipeptidyl peptidase-IV (DPP-4) inhibitors, most notably in the manufacturing pathway of vildagliptin, an antidiabetic drug widely used in the management of type 2 diabetes mellitus.

The market is driven by the sustained global demand for DPP-4 inhibitor-class antidiabetic therapeutics, given that type 2 diabetes affects over 500 million adults worldwide. Furthermore, the compound’s established role in active pharmaceutical ingredient (API) synthesis continues to attract investment from contract manufacturing organizations (CMOs) and fine chemical producers across Asia-Pacific and Europe, where pharmaceutical intermediate manufacturing is concentrated.

(2S)-1-(Chloroacetyl)-2-pyrrolidinecarbonitrile (CAS No. 207557-35-5) Market – View in Detailed Research Report

🔟 1️⃣ Hairui Chemical Co., Ltd.

Headquarters: Shanghai, China
Key Offering: High‑purity (S)-Chloroacetyl‑pyrrolidine nitrile intermediate for DPP‑4 inhibitor synthesis

Hairui Chemical has established a vertically integrated production line that delivers >99% ee intermediates to global API manufacturers. Their state‑of‑the‑art continuous‑flow reactors reduce batch times by 30% and enable rapid scale‑up for generic vildagliptin production.

Sustainability & Growth Initiatives:

• Implementation of green solvent systems and waste‑reduction protocols
• Investment in renewable energy for cGMP facilities
• Strategic partnerships with Tier‑1 API manufacturers for joint R&D

🧪 2️⃣ Finetech Industry Limited

Headquarters: Shenzhen, China
Key Offering: Enantiomerically pure intermediates for DPP‑4 and other peptide‑based therapeutics

Finetech’s flagship platform utilizes biocatalytic resolution to achieve >99% ee at a 20% lower cost than conventional routes. Their rapid‑release program supports fast‑track approvals for generics in emerging markets.

Sustainability & Growth Initiatives:

• Biocatalyst recycling to cut enzyme consumption by 35%
• Carbon‑neutral production target by 2035
• Collaboration with universities for next‑generation chiral catalysts

🏭 3️⃣ Shanghai Trustin Chemical Co., Ltd.

Headquarters: Shanghai, China
Key Offering: Bulk supply of (S)-Chloroacetyl‑pyrrolidine nitrile for API manufacturers

With a production capacity of 500 tonnes per year, Trustin serves the largest vildagliptin and sitagliptin generics manufacturers in Asia. Their robust QA framework ensures compliance with FDA, EMA, and USP standards.

Sustainability & Growth Initiatives:

• Zero‑waste policy for process solvents
• Investment in energy‑efficient distillation units
• Supplier audit program to enforce environmental compliance

🔬 4️⃣ PharmaBlock Sciences

Headquarters: Beijing, China
Key Offering: Custom synthesis of chiral intermediates for specialty APIs

PharmaBlock’s boutique services cater to high‑margin specialty drug developers. Their rapid‑prototyping platform accelerates the transition from discovery to commercial scale.

Sustainability & Growth Initiatives:

• Use of bio‑based reagents in synthesis
• Lifecycle assessment for each batch
• Partnership with global CDMOs for technology transfer

⚙️ 5️⃣ Changzhou Leixi Biological Technology Co., Ltd.

Headquarters: Changzhou, China
Key Offering: Enzymatic resolution of pyrrolidine intermediates for drug discovery

Leixi focuses on enzyme‑based chiral resolution, delivering high‑yield, low‑cost intermediates for academic and industrial research.

Sustainability & Growth Initiatives:

• Recycling of enzyme media for continuous processes
• Green chemistry training for R&D teams
• Collaboration with biotech firms on novel DPP‑4 inhibitors

🌱 6️⃣ MSN Laboratories

Headquarters: Mumbai, India
Key Offering: Bulk and technical grade intermediates for generic drug manufacturers

MSN’s integrated supply chain and cost‑effective production make it a preferred partner for Indian generics. Their regional distribution network covers over 30 states.

Sustainability & Growth Initiatives:

• Adoption of water‑recycling systems in plant operations
• ISO 14001 certification for environmental management
• Local sourcing of raw materials to reduce carbon footprint

💊 7️⃣ Aurobindo Pharma

Headquarters: Bangalore, India
Key Offering: High‑purity intermediates for API and generics production

Aurobindo’s global footprint and strong R&D pipeline position it as a leader in specialty drug manufacturing. Their 2025 target is to double the production of (S)-Chloroacetyl‑pyrrolidine intermediates.

Sustainability & Growth Initiatives:

• Renewable energy usage across all facilities
• Carbon‑neutral production goal by 2030
• Community engagement programs for local workforce development

🧪 8️⃣ Hetero Labs

Headquarters: Mumbai, India
Key Offering: Custom synthesis and analytical support for chiral intermediates

Hetero Labs provides end‑to‑end solutions, from synthesis to analytical validation, ensuring compliance with global pharmacopeial standards.

Sustainability & Growth Initiatives:

• Implementation of green chemistry protocols in all processes
• Waste‑to‑energy projects for organic solvent recovery
• Strategic alliances with academia for catalyst development

🔬 9️⃣ Divi’s Laboratories

Headquarters: Bangalore, India
Key Offering: Large‑scale production of (S)-Chloroacetyl‑pyrrolidine intermediates for API manufacturers

Divi’s leverages advanced process engineering to maintain high yield and purity, supporting the rapid roll‑out of generic DPP‑4 inhibitors.

Sustainability & Growth Initiatives:

• Zero‑discharge policy for chemical waste
• Investment in renewable energy for plant operations
• Continuous improvement programs for energy efficiency

🏗️ 🔟 Ningbo J&S Chempharm Co., Ltd.

Headquarters: Ningbo, China
Key Offering: High‑purity intermediates for specialty APIs and research

J&S Chempharm’s advanced purification systems ensure optical purity above 99% ee, meeting the stringent demands of global pharma clients.

Sustainability & Growth Initiatives:

• Implementation of closed‑loop water recycling
• Green solvent substitution program
• Partnerships with CDMOs for technology transfer

Download FREE Sample Report: (2S)-1-(Chloroacetyl)-2-pyrrolidinecarbonitrile (CAS No. 207557-35-5) Market – View in Detailed Research Report

Get Full Report Here: (2S)-1-(Chloroacetyl)-2-pyrrolidinecarbonitrile (CAS No. 207557-35-5) Market – View in Detailed Research Report

🌍 Outlook: The Future of (2S)-1-(Chloroacetyl)-2-pyrrolidinecarbonitrile Market

The market is poised for robust growth driven by the expanding demand for DPP‑4 inhibitors and the increasing focus on high‑purity chiral intermediates in generics and specialty APIs. Regulatory tightening on impurity limits and the push for green chemistry are expected to accelerate investment in advanced synthesis technologies. With Asia‑Pacific maintaining a dominant share, and Europe and North America steadily expanding their demand, the global market is projected to achieve a CAGR of 6.4% from 2025 to 2034.

📈 Key Trends Shaping the Market:

• Rapid scale‑up of generic DPP‑4 inhibitor production in India and China
• Adoption of continuous‑flow and biocatalytic processes to reduce costs
• Increasing demand for >99% ee intermediates driven by stringent regulatory standards
• Strategic collaborations between fine‑chemical producers and CDMOs for technology transfer
• Growth of sustainability initiatives, including renewable energy use and waste‑recycling programs